# PTEN Inhibition Suppresses Differentiation in Periodontal Ligament Stem Cells

**Authors:** Suphalak Phothichailert, Nunthawan Nowwarote, Chatvadee Kornsuthisopon, Supreda Suphanantachat Srithanyarat, Vorapat Trachoo, Worachat Namangkalakul, Hiroshi Egusa, Thanaphum Osathanon

PMC · DOI: 10.3390/ijms27042069 · International Journal of Molecular Sciences · 2026-02-23

## TL;DR

This study shows that inhibiting PTEN in periodontal ligament stem cells reduces their ability to form colonies, migrate, and differentiate into bone or fat cells.

## Contribution

The study reveals PTEN's role in regulating stem cell differentiation and tissue homeostasis in periodontal ligament cells.

## Key findings

- PTEN inhibition with VO-OHpic reduced colony formation and cell migration in PDLSCs.
- PTEN inhibition impaired osteogenic and adipogenic differentiation in PDLSCs.
- RNA sequencing showed upregulated TGF-β and calcium signaling pathways with PTEN inhibition.

## Abstract

Phosphatase and Tensin Homolog (PTEN) functions in numerous biological processes, encompassing cell proliferation, growth, self-renewal, and differentiation. This study examined the modulatory function of the PTEN inhibitor in periodontal ligament stem cells (PDLSCs). PDLSCs were treated with VO-OHpic at a concentration range from 0.625 to 5 μM. MTT assay and Coomassie Blue staining were conducted to determine cell viability and colony-forming unit ability, respectively. The scratch assay was employed to examine cell migration. Mineral deposition and intracellular lipid accumulation were assessed. The qRT-PCR and immunofluorescence were used to evaluate mRNA and protein expression, respectively. RNA sequencing was employed for transcriptomic analysis. VO-OHpic exposure showed no cytotoxic effects in PDLSCs; however, at 5 μM, it markedly decreased colony-forming efficiency and impaired cell migration. Under osteogenic induction conditions, 5 μM VO-OHpic markedly attenuated mineralisation and downregulated the osteogenic marker gene expression partly through ERK signalling. Indeed, VO-OHpic impaired intracellular lipid accumulation during adipogenic differentiation, as evidenced by reduced expression of adipogenic marker genes. RNA sequencing analysis revealed that VO-OHpic treatment upregulated genes in the TGF-β and calcium signalling pathways, suggesting a regulatory role in PDLSC differentiation. In conclusion, PTEN regulates PDLSC colony formation, migration, and differentiation, suggesting a pivotal role for PTEN in maintaining periodontal tissue homeostasis.

## Linked entities

- **Genes:** PTEN (phosphatase and tensin homolog) [NCBI Gene 5728]
- **Chemicals:** VO-OHpic (PubChem CID 66577002)

## Full-text entities

- **Genes:** LPL (lipoprotein lipase) [NCBI Gene 4023] {aka HDLCQ11, LIPD}, Eng (endoglin) [NCBI Gene 13805] {aka CD105, Endo, S-endoglin}, SRPX2 (sushi repeat containing protein X-linked 2) [NCBI Gene 27286] {aka BPP, CBPS, PMGX, RESDX, SRPUL}, BMP2 (bone morphogenetic protein 2) [NCBI Gene 650] {aka BDA2, BMP2A, SSFSC, SSFSC1}, DMP1 (dentin matrix acidic phosphoprotein 1) [NCBI Gene 1758] {aka ARHP, ARHR, DMP-1}, SP7 (Sp7 transcription factor) [NCBI Gene 121340] {aka OI11, OI12, OSX, osterix}, GAPDH (glyceraldehyde-3-phosphate dehydrogenase) [NCBI Gene 2597] {aka G3PD, GAPD, HEL-S-162eP}, Ptprc (protein tyrosine phosphatase receptor type C) [NCBI Gene 19264] {aka B220, CD45R, Cd45, L-CA, Ly-5, Lyt-4}, PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, HMOX1 (heme oxygenase 1) [NCBI Gene 3162] {aka HMOX1D, HO-1, HSP32, bK286B10}, PPARG (peroxisome proliferator activated receptor gamma) [NCBI Gene 5468] {aka CIMT1, FPLD3, GLM1, NR1C3, PPARG1, PPARG2}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, TGFBR1 (transforming growth factor beta receptor 1) [NCBI Gene 7046] {aka AAT5, ACVRLK4, ALK-5, ALK5, ESS1, LDS1}, RIEG2 (Rieger syndrome 2) [NCBI Gene 6012] {aka ARS, RGS2}, PTK2B (protein tyrosine kinase 2 beta) [NCBI Gene 2185] {aka CADTK, CAKB, FADK2, FAK2, PKB, PTK}, MAPK14 (mitogen-activated protein kinase 14) [NCBI Gene 1432] {aka CSBP, CSBP1, CSBP2, CSPB1, EXIP, Mxi2}, NEUROD2 (neuronal differentiation 2) [NCBI Gene 4761] {aka DEE72, EIEE72, NDRF, bHLHa1}, PTEN (phosphatase and tensin homolog) [NCBI Gene 5728] {aka 10q23del, BZS, CWS1, DEC, GLM2, MHAM}, TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}, BGLAP (bone gamma-carboxyglutamate protein) [NCBI Gene 632] {aka BGP, OC, OCN}, RUNX2 (RUNX family transcription factor 2) [NCBI Gene 860] {aka AML3, CBF-alpha-1, CBFA1, CCD, CCD1, CLCD}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, CEBPA (CCAAT enhancer binding protein alpha) [NCBI Gene 1050] {aka C/EBP-alpha, CEBP}, PPARA (peroxisome proliferator activated receptor alpha) [NCBI Gene 5465] {aka NR1C1, PPAR, PPAR-alpha, PPARalpha, hPPAR}, IBSP (integrin binding sialoprotein) [NCBI Gene 3381] {aka BNSP, BSP, BSP II, BSP-II, SP-II}, Cd44 (CD44 antigen) [NCBI Gene 12505] {aka HERMES, Ly-24, Pgp-1}, MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 2475] {aka FRAP, FRAP1, FRAP2, RAFT1, RAPT1, SKS}, RNASE1 (ribonuclease A family member 1, pancreatic) [NCBI Gene 6035] {aka RAC1, RIB1, RNS1}, ADM (adrenomedullin) [NCBI Gene 133] {aka AM, PAMP}, ATHS (atherosclerosis susceptibility (lipoprotein associated)) [NCBI Gene 470] {aka ALP}, SMAD2 (SMAD family member 2) [NCBI Gene 4087] {aka CHTD8, JV18, JV18-1, LDS6, MADH2, MADR2}, HAS3 (hyaluronan synthase 3) [NCBI Gene 3038], Nt5e (5' nucleotidase, ecto) [NCBI Gene 23959] {aka 2210401F01Rik, 5'-NT, CD73, NT, Nt5, eNT}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, MAPK8 (mitogen-activated protein kinase 8) [NCBI Gene 5599] {aka JNK, JNK-46, JNK1, JNK1A2, JNK21B1/2, PRKM8}, MAPK1 (mitogen-activated protein kinase 1) [NCBI Gene 5594] {aka ERK, ERK-2, ERK2, ERT1, MAPK2, NS13}, PIK3R1 (phosphoinositide-3-kinase regulatory subunit 1) [NCBI Gene 5295] {aka AGM7, GRB1, IMD36, p85, p85-ALPHA, p85alpha}, RAMP1 (receptor activity modifying protein 1) [NCBI Gene 10267], PRRT2 (proline rich transmembrane protein 2) [NCBI Gene 112476] {aka BFIC2, BFIS2, DSPB3, DYT10, EKD1, FICCA}, COL1A1 (collagen type I alpha 1 chain) [NCBI Gene 1277] {aka CAFYD, EDSARTH1, EDSC, OI1, OI2, OI3}, SPP1 (secreted phosphoprotein 1) [NCBI Gene 6696] {aka BNSP, BSPI, ETA-1, OPN}, Thy1 (thymus cell antigen 1, theta) [NCBI Gene 21838] {aka CD90, T25, Thy-1, Thy-1.2, Thy1.1, Thy1.2}, AVIL (advillin) [NCBI Gene 10677] {aka ADVIL, DOC6, NPHS21, p92}, NFE2L2 (NFE2 like bZIP transcription factor 2) [NCBI Gene 4780] {aka IMDDHH, NRF2, Nrf-2}, NANOG (Nanog homeobox) [NCBI Gene 79923], TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}
- **Diseases:** intervertebral disc degeneration (MESH:D055959), cartilage endplate degeneration (MESH:D002357), alveolar (MESH:D002282), periodontal disease (MESH:D010510), mitochondrial dysfunction (MESH:D028361), Cowden syndrome (MESH:D006223), hereditary cancer predisposition (MESH:D009386), injury to (MESH:D014947), OM (MESH:D012516), periodontitis (MESH:D010518), inflammation (MESH:D007249), bone loss (MESH:D001847), cytotoxic (MESH:D064420), calcification (MESH:D002114), infection (MESH:D007239)
- **Chemicals:** TRIzol (MESH:C411644), Oil Red O (MESH:C011049), vanadium (MESH:D014639), Lipid (MESH:D008055), CO2 (MESH:D002245), L-glutamine (MESH:D005973), SYBR Green (MESH:C098022), tetrazolium (MESH:D013778), SB431542 (MESH:C459179), water (MESH:D014867), phospholipids (MESH:D010743), cetylpyridinium chloride monohydrate (MESH:D002594), Alizarin Red S (MESH:C004468), glycine (MESH:D005998), Calcium (MESH:D002118), SP600125 (MESH:C432165), formaldehyde (MESH:D005557), ethanol (MESH:D000431), DMSO (MESH:D004121), DAPI (MESH:C007293), Coomassie Blue (MESH:C048139), L-ascorbic acid (MESH:D001205), VO-OHpic (MESH:C000600334), penicillin (MESH:D010406), sodium phosphate (MESH:C018279), formazan (MESH:D005562), bpVpic (MESH:C119540), Alexa Flour 488 (-), DCU (MESH:C000948), PI (MESH:D011419), streptomycin (MESH:D013307), SB203580 (MESH:C093642), TritonX-100 (MESH:D017830), EDTA (MESH:D004492), MTT (MESH:C070243), indomethacin (MESH:D007213), IBMX (MESH:D015056), U0126 (MESH:C113580), FITC (MESH:D016650), dexamethasone (MESH:D003907), beta-glycerophosphate (MESH:C031463), amphotericin B (MESH:D000666), Fluoresceine (MESH:D019793)
- **Species:** Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12940904/full.md

## Figures

9 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12940904/full.md

## References

52 references — full list in the complete paper: https://tomesphere.com/paper/PMC12940904/full.md

---
Source: https://tomesphere.com/paper/PMC12940904